Vincristine Sulfate
FDA-approved product (injectable, injection), marketed as Marqibo Kit, Oncovin, Vincasar Pfs and 3 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Vinca alkaloids and analogues
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli47.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae36.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Vincristine Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Cetrorelix AcetateExisting use: Ovulation Inhibition, Positive regulation of ovulation63.2% AI-predicted activityagainst MRSA50+ registered studies
- HexachloropheneExisting use: Phenol and derivatives63.2% AI-predicted activityagainst MRSALab records exist3 registered studies
- LorlatinibExisting use: Cancer, Lymphoma, Neoplasm and 1 more63.1% AI-predicted activityagainst MRSA50+ registered studies
- Alectinib HydrochlorideExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma63.0% AI-predicted activityagainst MRSA13 registered studies
- AlpelisibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 2 more63.0% AI-predicted activityagainst MRSA50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer62.9% AI-predicted activityagainst MRSA13 registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma62.9% AI-predicted activityagainst MRSA50+ registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder62.8% AI-predicted activityagainst MRSANo documented evidence found
- TacrolimusExisting use: Atopic eczema, Delayed Graft Function, Eczematoid dermatitis and 3 more62.5% AI-predicted activityagainst MRSA50+ registered studies
- Rezafungin AcetateExisting use: Candidemia, Candidiasis, Candidiasis, Invasive62.4% AI-predicted activityagainst MRSA5 registered studies
- AvapritinibExisting use: Cancer, Gastrointestinal stromal tumor, Neoplasm62.2% AI-predicted activityagainst MRSA30 registered studies
- Ceruletide DiethylamineExisting use: Tests for bile duct patency62.2% AI-predicted activityagainst MRSANo documented evidence found
Registered studies
A registration describes a study; it does not establish a positive result.
Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin
NCT00022178 · start 1998-12
Registered record
- Registry ID
- NCT00022178
- Conditions
- Carcinoma of Unknown Primary
- Interventions
- cisplatin; cyclophosphamide; doxorubicin hydrochloride; epirubicin hydrochloride; fluorouracil; vincristine sulfate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 1998-12
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCarcinoma of Unknown PrimaryInterventioncisplatin; cyclophosphamide; doxorubicin hydrochloride; epirubicin hydrochloride +2 morePhasePhase 3Registry statusUnknownCombination Chemotherapy in Treating Children With Progressive Brain Tumors
NCT00002944 · start 1997-04
Registered record
- Registry ID
- NCT00002944
- Conditions
- Brain Tumors; Central Nervous System Tumors
- Interventions
- carboplatin; lomustine; procarbazine hydrochloride; thioguanine; vincristine sulfate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1997-04
- Completion
- 2012-04
- Enrolment
- 428
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBrain Tumors; Central Nervous System TumorsInterventioncarboplatin; lomustine; procarbazine hydrochloride; thioguanine +1 morePhasePhase 3Registry statusCompletedChemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease
NCT00002827 · start 1996-10
Registered record
- Registry ID
- NCT00002827
- Conditions
- Cardiac Toxicity; Lymphoma
- Interventions
- bleomycin sulfate; filgrastim; dexrazoxane hydrochloride; doxorubicin hydrochloride; etoposide; vincristine sulfate; low-LET cobalt-60 gamma ray therapy; low-LET electron therapy; low-LET photon therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1996-10
- Completion
- 2008-06
- Enrolment
- 294
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCardiac Toxicity; LymphomaInterventionbleomycin sulfate; filgrastim; dexrazoxane hydrochloride; doxorubicin hydrochloride +5 morePhasePhase 3Registry statusCompletedCombination Chemotherapy in Treating Children With Lymphoma
NCT00002590 · start 1994-07
Registered record
- Registry ID
- NCT00002590
- Conditions
- Lymphoma
- Interventions
- filgrastim; cyclophosphamide; cytarabine; daunorubicin hydrochloride; doxorubicin hydrochloride; etoposide; leucovorin calcium; methotrexate; pegaspargase; prednisone; thioguanine; vincristine sulfate; radiation therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1994-07
- Completion
- 2007-03
- Enrolment
- 221
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLymphomaInterventionfilgrastim; cyclophosphamide; cytarabine; daunorubicin hydrochloride +9 morePhasePhase 2Registry statusCompletedCombination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
NCT00002494 · start 1992-05
Registered record
- Registry ID
- NCT00002494
- Conditions
- Leukemia; Lymphoma
- Interventions
- cyclophosphamide; cytarabine; dexamethasone; doxorubicin hydrochloride; etoposide; ifosfamide; leucovorin calcium; mesna; methotrexate; prednisone; therapeutic hydrocortisone; vincristine sulfate; low-LET cobalt-60 gamma ray therapy; low-LET photon therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1992-05
- Completion
- 2006-01
- Enrolment
- 134
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLeukemia; LymphomaInterventioncyclophosphamide; cytarabine; dexamethasone; doxorubicin hydrochloride +10 morePhasePhase 2Registry statusCompleted